Drugs / Umbilical Cord Blood-Derived Lymphocyte Therapy
Umbilical Cord Blood-Derived Lymphocyte Therapy
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01630564 | Mar 2013 → May 2018 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01729091 | Jun 2013 → Jun 2024 | plasma cell leukemia, plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Blood-Derived Lymphocyte Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01729091 ↗ |
| Modality | Cell therapy | “ex vivo-expanded T-cells” NCT01630564 ↗ |
| Route | Intravenous | “Given IV” NCT01729091 ↗ |